These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 16570288)
1. SH-7, a new synthesized shikonin derivative, exerting its potent antitumor activities as a topoisomerase inhibitor. Yang F; Chen Y; Duan W; Zhang C; Zhu H; Ding J Int J Cancer; 2006 Sep; 119(5):1184-93. PubMed ID: 16570288 [TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity, apoptosis induction and downregulation of MDR-1 expression by the anti-topoisomerase II agent, salvicine, in multidrug-resistant tumor cells. Miao ZH; Tang T; Zhang YX; Zhang JS; Ding J Int J Cancer; 2003 Aug; 106(1):108-15. PubMed ID: 12794765 [TBL] [Abstract][Full Text] [Related]
3. Shikonin, a Chinese plant-derived naphthoquinone, induces apoptosis in hepatocellular carcinoma cells through reactive oxygen species: A potential new treatment for hepatocellular carcinoma. Gong K; Li W Free Radic Biol Med; 2011 Dec; 51(12):2259-71. PubMed ID: 22011623 [TBL] [Abstract][Full Text] [Related]
4. MFTZ-1, an actinomycetes subspecies derived antitumor macrolide, functions as a novel topoisomerase II poison. Xie CY; Zhu H; Lin LP; Miao ZH; Geng MY; Cai YJ; Chen Y; Zhao HJ; Luo HB; Zhang XW; Fan LM; Shen YM; Ding J Mol Cancer Ther; 2007 Nov; 6(11):3059-70. PubMed ID: 18025289 [TBL] [Abstract][Full Text] [Related]
5. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers. Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333 [TBL] [Abstract][Full Text] [Related]
6. Antitumor Effect of Labbozzetta M; Poma P; Occhipinti C; Sajeva M; Notarbartolo M Molecules; 2022 Jun; 27(13):. PubMed ID: 35807446 [TBL] [Abstract][Full Text] [Related]
7. High antineoplastic activity of new heterocyclic compounds in cancer cells with resistance against classical DNA topoisomerase II-targeting drugs. Lage H; Aki-Sener E; Yalcin I Int J Cancer; 2006 Jul; 119(1):213-20. PubMed ID: 16450374 [TBL] [Abstract][Full Text] [Related]
8. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I. Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421 [TBL] [Abstract][Full Text] [Related]
9. R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II. Zhu H; Huang M; Yang F; Chen Y; Miao ZH; Qian XH; Xu YF; Qin YX; Luo HB; Shen X; Geng MY; Cai YJ; Ding J Mol Cancer Ther; 2007 Feb; 6(2):484-95. PubMed ID: 17308047 [TBL] [Abstract][Full Text] [Related]
10. A novel epoxypropoxy flavonoid derivative and topoisomerase II inhibitor, MHY336, induces apoptosis in prostate cancer cells. Patra N; De U; Kang JA; Kim JM; Ahn MY; Lee J; Jung JH; Chung HY; Moon HR; Kim HS Eur J Pharmacol; 2011 May; 658(2-3):98-107. PubMed ID: 21376033 [TBL] [Abstract][Full Text] [Related]
11. CIP-36, a novel topoisomerase II-targeting agent, induces the apoptosis of multidrug-resistant cancer cells in vitro. Cao B; Chen H; Gao Y; Niu C; Zhang Y; Li L Int J Mol Med; 2015 Mar; 35(3):771-6. PubMed ID: 25592869 [TBL] [Abstract][Full Text] [Related]
12. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998 [TBL] [Abstract][Full Text] [Related]
13. CS1 is a novel topoisomerase IIα inhibitor with favorable drug resistance profiles. Shen Y; Chen W; Zhao B; Hao H; Li Z; Lu C; Shen Y Biochem Biophys Res Commun; 2014 Oct; 453(3):302-8. PubMed ID: 25242524 [TBL] [Abstract][Full Text] [Related]
14. Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage. Gieseler F; Bauer E; Nuessler V; Clark M; Valsamas S Leukemia; 1999 Nov; 13(11):1859-63. PubMed ID: 10557063 [TBL] [Abstract][Full Text] [Related]
15. BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo. Demarquay D; Huchet M; Coulomb H; Lesueur-Ginot L; Lavergne O; Camara J; Kasprzyk PG; Prévost G; Bigg DC Cancer Res; 2004 Jul; 64(14):4942-9. PubMed ID: 15256467 [TBL] [Abstract][Full Text] [Related]
16. Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells. Minderman H; Wrzosek C; Cao S; Utsugi T; Kobunai T; Yamada Y; Rustum YM Cancer Chemother Pharmacol; 2000; 45(1):78-84. PubMed ID: 10647506 [TBL] [Abstract][Full Text] [Related]
17. A rational design strategy of the novel topoisomerase II inhibitors for the synthesis of the 4-O-(2-pyrazinecarboxylic)-4'-demethylepipodophyllotoxin with antitumor activity by diminishing the relaxation reaction of topoisomerase II-DNA decatenation. Zhao W; Chen L; Li HM; Wang DJ; Li DS; Chen T; Yuan ZP; Tang YJ Bioorg Med Chem; 2014 Jun; 22(11):2998-3007. PubMed ID: 24775914 [TBL] [Abstract][Full Text] [Related]
18. Quercetin-3-O-glucoside induces human DNA topoisomerase II inhibition, cell cycle arrest and apoptosis in hepatocellular carcinoma cells. Sudan S; Rupasinghe HP Anticancer Res; 2014 Apr; 34(4):1691-9. PubMed ID: 24692698 [TBL] [Abstract][Full Text] [Related]
19. [Antitumor effect and mechanism of shikonin derivative SYUNZ-7]. Huang H; Xie BF; Zhu XF; Feng GK; Zhou JM; Wang Y; Wu HQ; Huang ZS; Gu LQ; Liu ZC Ai Zheng; 2005 Dec; 24(12):1453-8. PubMed ID: 16351791 [TBL] [Abstract][Full Text] [Related]
20. Reactive oxygen species elicit apoptosis by concurrently disrupting topoisomerase II and DNA-dependent protein kinase. Lu HR; Zhu H; Huang M; Chen Y; Cai YJ; Miao ZH; Zhang JS; Ding J Mol Pharmacol; 2005 Oct; 68(4):983-94. PubMed ID: 16024664 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]